A phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients with HER2-negative, locally advanced, or metastatic breast cancer
- Abramson, V.G.
- Oliveira, M.
- Cervantes, A.
- Wildiers, H.
- Patel, M.R.
- Bauer, T.M.
- Bedard, P.L.
- Becerra, C.
- Richey, S.
- Wei, M.C.
- Reyner, E.
- Bond, J.
- Cui, N.
- Wilson, T.R.
- Moore, H.M.
- Saura, C.
- Krop, I.E.
ISSN: 1573-7217, 0167-6806
Ano de publicación: 2019
Volume: 178
Número: 1
Páxinas: 121-133
Tipo: Artigo